Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523500 | 1.00 | PDE4B (0.54) | PDE4BKMT2AL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL12527110 | 1.00 | PDE4B (0.54) | PDE4BKMT2AL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL523841 | 1.00 | PDE4B (0.54) | PDE4BKMT2AL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL3547026 | 1.00 | PDE4B (0.54) | PDE4BKMT2AL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL9186129 | 0.92 | SMN1; SMN2 (0.51) | PDE4BKMT2AL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL9186123 | 0.92 | SMN1; SMN2 (0.51) | PDE4BKMT2AL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL5744757 | 0.91 | PDE4B (0.52) | PDE4BKMT2AL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL5744759 | 0.91 | PDE4B (0.52) | PDE4BKMT2AL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL5744756 | 0.91 | PDE4B (0.52) | PDE4BKMT2AL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL21551304 | 0.91 | ALDH1A1 (0.46) | PDE4BKMT2ASMN1; SMN2SYKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417128-B1 | 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES AS ADP RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-03-02 | — | — | EP | disclosed |
| US-8288385-B2 | 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20120028989-A1 | 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2012-02-02 | — | — | US | disclosed |
| US-5266569-A | Azatricyclo carboxylic acids useful as anti-bacterial agents | PFIZER INC. (US) | 1993-11-30 | — | — | US | disclosed |
| US-5164402-A | Bactericides | PFIZER INC (US) | 1992-11-17 | — | — | US | disclosed |
| EP-0413455-A2 | Azabicyclo quinolone carboxylic acids | PFIZER INC. (US) | 1991-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028989-A1 | 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES | P2RY12, P2RY13, P2RY6 | PDE4B 594/4885KMT2A 3240/4885L3MBTL1 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.